This study is a 4-week, randomized, double-blind, parallel-group, placebo-controlled monotherapy study in patients with treatment-resistant major depression. After confirmation of treatment-resistance in a prospective treatment period with citalopram, each patient will be treated with either EVT 101 once daily or placebo for 28 consecutive days.
No linked publications found in PubMed
Inclusion Criteria: * Major Depressive Disorder * Current episode of major depression that has not benefited from at least 1 but no more than 3 adequate treatment regimens * Has as score of \>/= 18 on the Ham-D-17 Exclusion Criteria: * Pregnant or breast-feeding women * Evidence of age-related cognitive decline or mild dementia * At imminent risk of committing suicide * Has with the exception of major depression, a serious medical or neurological illness, including seizure disorder, stroke, dementia, or Parkinson disease * Has an established diagnosis of bipolar disorder, hypomania, schizoaffective disorder, major depression with psychotic features or schizophrenia * Has had a substance or alcohol abuse or dependence disorder (except nicotine and caffeine) in the 1 year before screening